Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?

The EGFR gene is a major therapeutic target in advanced Non-small cell lung cancer (NSCLC). Two reversible tyrosine kinase inhibitors, Erlotinib and Gefitinib, have been validated and registered for the treatment of NSCLC. Gefitinib has a label that is limited to NSCLC carrying mutations in the kinase domain of the EGFR gene, while the label of Erlotinib also includes second line treatment of patients with undefined EGFR status in their tumor, based on an early randomized study that showed a small benefit in such unselected population (1).